As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million compared to $22.8 million as of December 31, 2024. The Company believes its cash and cash equivalents as of December 31, 2025, together with the proceeds from the private placement completed in January 2026 will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the first quarter of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics files to sell 12.58M shares of common stock for holders
- Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating
- Aprea Highlights Encouraging Phase 1 Data for APR-1051
- Aprea Therapeutics announces additional clinical activity for APR-1051
- Aprea announces expansions of its global intellectual property estate